Lanham O'Dell & Company, Inc. - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 265 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.

Quarter-by-quarter ownership
Lanham O'Dell & Company, Inc. ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$309,800
-2.8%
20,0000.0%0.17%
+8.1%
Q1 2024$318,800
-8.1%
20,000
-3.1%
0.16%
-33.2%
Q4 2023$347,042
+41.4%
20,645
-1.7%
0.24%
+19.3%
Q3 2023$245,490
-13.0%
21,0000.0%0.20%
-21.1%
Q2 2023$282,240
-18.9%
21,0000.0%0.26%
-33.2%
Q1 2023$348,180
-6.4%
21,000
+5.0%
0.38%
-52.8%
Q4 2022$372,000
+44.2%
20,000
-0.7%
0.81%
-11.3%
Q3 2022$258,000
+17.3%
20,145
-24.0%
0.92%
+435.1%
Q1 2022$220,000
-35.1%
26,500
-47.0%
0.17%
-36.2%
Q4 2021$339,00050,0000.27%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q2 2024
NameSharesValueWeighting ↓
Consonance Capital Management LP 17,875,655$94,920,0009.39%
TANAKA CAPITAL MANAGEMENT INC 283,334$1,505,0004.86%
GABLES CAPITAL MANAGEMENT INC. 490,564$2,606,0001.84%
MANGROVE PARTNERS IM, LLC 2,508,838$13,322,0001.61%
Broadfin Capital, LLC 880,303$4,674,0000.86%
Atom Investors LP 1,012,355$5,376,0000.37%
Capital Impact Advisors, LLC 179,868$948,0000.36%
KNOTT DAVID M 151,415$804,0000.34%
EMERALD ADVISERS, LLC 1,175,958$6,244,0000.29%
CADENCE CAPITAL MANAGEMENT LLC 371,075$1,970,0000.28%
View complete list of CATALYST PHARMACEUTICALS INC shareholders